Ionis Pharmaceuticals (Ionis Pharmaceuticals) Pre-Tax Income : $-334.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Ionis Pharmaceuticals's pretax income for the three months ended in Dec. 2023 was $-2.8 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-334.0 Mil. Ionis Pharmaceuticals's pretax margin was -0.85%.

During the past 13 years, Ionis Pharmaceuticals's highest Pretax Margin was 30.18%. The lowest was -43.92%. And the median was -16.94%.

Ionis Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Ionis Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Pre-Tax Income Chart

Ionis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

338.77

-134.55

-29.15

-257.99

-333.97

Ionis Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-44.33	-112.94	-77.45	-140.81	-2.77

Competitive Comparison of Ionis Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Ionis Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ionis Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Ionis Pharmaceuticals's Pre-Tax Income falls into.

Ionis Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Ionis Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-353.711	+	101.222	+	-75.597	+	0	+	-5.879
	=	-334.0

Ionis Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-6.112	+	25.763	+	-20.849	+	0	+	-1.569
	=	-2.8

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-334.0 Mil.

Ionis Pharmaceuticals (NAS:IONS) Pre-Tax Income Explanation

Ionis Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-2.767	/	324.505
	=	-0.85%

During the past 13 years, Ionis Pharmaceuticals's highest Pretax Margin was 30.18%. The lowest was -43.92%. And the median was -16.94%.

Ionis Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

IONS:Mexico ISI:Germany ISI:Germany

Address

2855 Gazelle Court, Carlsbad, CA, USA, 92010

Website

https://www.ionispharma.com

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Executives

Brian Birchler	officer: EVP, Corp and Development Ops	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Patrick R. O'neil	officer: SVP, Legal and General Counsel	C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier	officer: Chief Corp Dev and Cml Officer	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eugene Schneider	officer: EVP, Chf Clinical Develop Offc	C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Joseph Baroldi	officer: Chief Business Officer	C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Eric Swayze	officer: SVP, Research	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Brett P Monia	director, officer: Senior Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Richard S Geary	officer: Senior Vice President	2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen	officer: SVP, Finance and CFO	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett	officer: Vice President	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
B Lynne Parshall	director, officer: Executive Vice President, CFO	2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Iii Klein	director	C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Allene M. Diaz	director	C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Spencer R Berthelsen	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Frederick T Muto	director	2855 GAZELLE COURT, CARLSBAD CA 92010